X4 Pharmaceuticals has secured US approval for Xolremdi (mavorixafor), for the treatment of WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokat 30 April 2024
Interpharma, the association of research-based pharmaceutical companies in Switzerland, has called on lawmakers to reconsider a cost containment package which i 29 April 2024
The UK’s second-largest drugmaker, GSK, expects to hear by the end of August whether the US regulator will expand the label for Jemperli (dostarlimab). 25 April 2024
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.